Cohort origin overview. Patients from nine centers in four countries and two continents were enrolled. The largest cohort in terms of patient number, the Austrian cohort, was employed for the development and initial validation of the AI system. The AI-based imaging biomarker output by the AI system was validated using the remaining patients from eight centers. Credit: The Lancet Digital Health (2024). DOI: 10.1016/S2589-7500(23)00265-0

Authors: Medical University of Vienna

Source: Medical Xpress

Cardiac amyloidosis is a serious disease in which abnormal proteins (amyloids) accumulate in the heart muscle and impair heart function. As the disease leads to serious complications such as heart insufficiency and, in many cases, death if left untreated, early diagnosis is essential in order to start treatment in good time.

An international research team led by MedUni Vienna has now developed and tested an AI system that can be used to automatically and reliably detect cardiac amyloidosis. The results of the study have just been published in The Lancet Digital Health.

The new AI system was developed and validated using data sets from 16,000 patients who underwent a scintigraphy imaging examination at nine institutions in Europe and Asia, including Vienna General Hospital, between 2010 and 2020. Scintigraphy is a nuclear medicine procedure that is used to diagnose cancer, thyroid, kidney and heart disease, among other things.

The new AI tool created as part of the research work led by Christian Nitsche (MedUni Vienna's Department of Medicine II) and Marcus Hacker (MedUni Vienna's Department of Biomedical Imaging and Image-guided Therapy) can automatically recognise cardiac amyloidosis during a scintigraphy, thereby significantly speeding up the diagnosis.

At least as reliable as doctors

The AI application was not only developed as part of the large-scale study, but also tested for accuracy compared to the diagnostic performance of doctors. "We found that the system can consistently recognise cardiac amyloidosis at least as reliably as medical experts," report lead authors Clemens Spielvogel and David Haberl from MedUni Vienna's Department of of Biomedical Imaging and Image-guided Therapy.

The research team also analysed possible correlations between the diagnoses made by the AI system and the occurrence of heart failure and the risk of death. It was found that scintigraphy patients in whom the AI system predicts cardiac amyloidosis have twice the risk of death and a more than 17-fold higher risk of heart failure than patients without such a result.

Cardiac amyloidosis is a rare and often late-diagnosed but serious disease that can hide behind heart insufficiency, for example, more often than previously thought. In 2020, disease-modifying therapies that can halt the progression of cardiac amyloidosis were approved in the European Union for the first time. However, since existing protein deposits and thus the disease cannot be reversed, early and precise diagnosis plays an important role for patients.

"In the future, our findings and the technology we have developed could enable screening for cardiac amyloidosis among all scintigraphy patients, with the AI system evaluating the image data in parallel with doctors," says Clemens Spielvogel.

More information

This article was written by Medical University of Vienna from Medical Xpress and was legally licensed through the DiveMarketplace by Industry Dive. Please direct all licensing questions to [email protected].

Medical Xpress Logo

Disclaimer: Novartis Ireland Limited accepts no responsibility for the content, accuracy, interpretation or out of use of the information contained within this article or its use of linked websites.

Rate this content: 
No votes yet
IE438009 | May 2024

Ask Speakers


Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website Adverse events can also be reported to Novartis preferably at, by emailing [email protected] or by calling (01) 2080 612.